GLUE

Monte Rosa Therapeutics Inc

16.52

Jul 31 • 3:59 PM ET -6.16 (-27.16%)

16.72

Aftermarket • 5:34 PM ET +0.20 (1.21%)

Healthcare Biotechnology USA Small NASD

Today, 8:30 AMNovo Nordisk ziltivekimab Phase 3 CV trial failure triggers 39% GLUE premarket plunge

Peers: NRIX KYMR RCUS TNGX CGON NUVL RYTM BMRN INCY KRYS

| Held by: VTI XBI IWM VXF AVUV IWO VTWO IBB BSVO SCHA

Scroll to Statements

Index	RUT
Market Cap	1.40B
Enterprise Value	768.44M
Income	-130.01M
Sales	42.95M
Book/sh	6.19
Cash/sh	7.89
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	150
IPO	Jun 24, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	32.49
P/B	2.67
P/C	2.09
P/FCF	-
EV/EBITDA	-
EV/Sales	17.89
Quick Ratio	9.54
Current Ratio	9.54
Debt/Eq	0.07
LT Debt/Eq	0.07
Option/Short	Yes / Yes

EPS (ttm)	-1.63
EPS next Y	-1.84
EPS next Q	-0.38
EPS this Y	-260.13%
EPS next Y	-10.86%
EPS next 5Y	-
EPS past 3/5Y	41.29% 10.62%
Sales past 3/5Y	- -
EPS Y/Y TTM	-2335.85%
Sales Y/Y TTM	-73.07%
EPS Q/Q	-178.84%
Sales Q/Q	-95.04%
Earnings	May 07 BMO
EPS/Sales Surpr.	-14.97% -61.88%

Insider Own	29.26%
Insider Trans	-0.72%
Inst Own	85.70%
Inst Trans	36.87%
ROA	-23.02%
ROE	-32.62%
ROIC	-23.36%
Gross Margin	80.59%
Oper. Margin	-345.21%
Profit Margin	-302.69%
SMA20	-27.85%
SMA50	-20.50%
SMA200	-9.03%
Trades

Shs Outstand	84.32M
Shs Float	59.76M
Short Float	28.77%
Short Ratio	14.34
Short Interest	17.20M
52W High	25.77 -35.89%
52W Low	4.12 300.97%
Volatility	6.92% 6.77%
ATR (14)	1.91
RSI (14)	29.65
Beta	1.57
Rel Volume	6.23
Avg Volume	1.20M
Volume	7,467,219

Perf Week	-27.48%
Perf Month	-31.22%
Perf Quarter	-13.73%
Perf Half Y	-22.66%
Perf YTD	5.36%
Perf Year	233.74%
Perf 3Y	133.66%
Perf 5Y	-32.63%
Perf 10Y	-
Recom	1.00
Target Price	30.67
Prev Close	22.68
Price	16.52
Change	-27.16%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $11
Feb-15-24	Initiated	Wedbush	Outperform	$11
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$18
Oct-13-22	Initiated	UBS	Buy	$22
Aug-15-22	Initiated	Jefferies	Buy	$20
Apr-28-22	Initiated	Credit Suisse	Neutral	$19
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$19
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20

Jul-02-26 04:01PM	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-26 04:01PM	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.81%
May-20-26 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.09%
May-07-26 09:18AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:00AM	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
04:01PM	Loading…
May-05-26 04:01PM	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.37%
Apr-20-26 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors (GlobeNewswire)
Mar-17-26 07:33AM	Monte Rosa Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates (GlobeNewswire)
Mar-16-26 07:00AM	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Mar-05-26 07:40AM	Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-24-26 07:00AM	Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) (GlobeNewswire)
Feb-23-26 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-17-26 08:15AM	NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates (Zacks)
Feb-05-26 11:37AM	3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher (MarketBeat)
08:39PM	Loading…
Jan-16-26 08:39PM	Staar Surgical, Alumis, and More Stocks See Action From Activist Investors (Barrons.com)
Jan-08-26 10:49PM	Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +8.72%
11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
08:55AM	Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jan-07-26 04:01PM	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +45.41%
12:00PM	Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why (Zacks)
11:21AM	Stocks Hover Near Record Highs on Mixed US Economic News (Barchart)
10:07AM	Stocks Supported by Lower Bond Yields (Barchart)
07:00AM	Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects (GlobeNewswire)
Jan-06-26 04:05PM	Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results (GlobeNewswire) +11.18%
Dec-17-25 07:11AM	Monte Rosa Therapeutics announces data from Phase 1/2 study of MRT-2359 (TipRanks) -10.24%
Dec-16-25 04:22PM	Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High (Investor's Business Daily) +13.43%
07:00AM	Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations (GlobeNewswire)
Dec-15-25 04:01PM	Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results (GlobeNewswire)
Nov-08-25 11:30AM	Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases (GlobeNewswire)
08:30AM	Loading…
Nov-06-25 08:30AM	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.69%
07:34AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Nov-03-25 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.07%
Oct-24-25 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases (GlobeNewswire) +7.32%
Sep-30-25 11:42AM	Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects (Insider Monkey)
Sep-16-25 09:49AM	Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis (Zacks) -6.64%
08:01AM	Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock? (Zacks)
Sep-15-25 12:31PM	Novartis returns to Monte Rosa for second time in a year with $5.7bn deal (Pharmaceutical Technology) +44.07%
08:24AM	Monte Rosa surges premarket on Novartis collaboration deal (Investing.com)
07:15AM	Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics (Reuters)
07:00AM	Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases (GlobeNewswire)
05:39AM	Novartis dives deeper into protein degraders with second Monte Rosa deal (BioPharma Dive)
Sep-02-25 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 08:25AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:22AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-06-25 06:00PM	Certara, Inc. (CERT) Q2 Earnings Miss Estimates (Zacks) -9.83%
Jul-22-25 07:30AM	Monte Rosa doses first subjects in trial of MRT-8102 for inflammatory conditions (Clinical Trials Arena)
Jul-21-25 07:00AM	Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases (GlobeNewswire)
Jul-03-25 02:15PM	Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines (GlobeNewswire)
Jun-11-25 08:38AM	Monte Rosa Therapeutics receives FDA clearance for MRT-8102 IND (Pharmaceutical Business Review)
Jun-10-25 07:00AM	Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet (Zacks)
May-28-25 07:00AM	Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 08:25AM	Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates (Zacks) +9.61%
07:21AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-06-25 08:20AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.69%
May-01-25 08:15AM	Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-28-25 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer (GlobeNewswire)
Mar-24-25 04:46PM	Monte Rosa Therapeutics: Exercise Extreme Caution (SeekingAlpha)
Mar-21-25 12:04PM	Monte Rosa Therapeutics Inc (GLUE) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com) -17.85%
09:33AM	Mixed data results for two Monte Rosa molecular glue degraders (Clinical Trials Arena)
Mar-20-25 12:42PM	Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 (SeekingAlpha) +5.37%
12:00PM	Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
10:35AM	Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates (Zacks)
07:00AM	Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs (GlobeNewswire)
Mar-11-25 07:00AM	Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -6.11%
Jan-11-25 07:27AM	Monte Rosa Therapeutics provide corporate update, key milestones 2025 (TipRanks)
Jan-10-25 07:00AM	Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 (GlobeNewswire)
Jan-06-25 07:00AM	Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-24 07:00AM	Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors (GlobeNewswire)
Dec-11-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer (GlobeNewswire) -9.85%
07:00AM	Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders (GlobeNewswire)
Dec-06-24 07:11AM	Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study (TipRanks) +6.57%
Dec-05-24 07:00AM	Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors (GlobeNewswire)
Dec-02-24 05:44PM	Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? (Zacks)
Nov-26-24 07:00AM	Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-15-24 09:55AM	Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet (Zacks) -8.73%
Nov-13-24 07:00AM	Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -5.48%
Nov-07-24 08:35AM	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice (Zacks)
Oct-30-24 09:55AM	Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade (Zacks)
Oct-29-24 11:50AM	Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler (TipRanks)
10:57AM	Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis (GuruFocus.com)
Oct-28-24 05:40PM	Monte Rosa Almost Doubles Up 94% On A Massive Deal With Novartis (Investor's Business Daily) +93.87%
02:26PM	This Biotech Stock Has Doubled Its Value Today Here's Why (Investopedia)
02:10PM	Monte Rosa Stock Doubles Up 127% On A Massive Deal With Novartis (Investor's Business Daily)
08:53AM	Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs (Reuters)
08:46AM	Why Is Monte Rosa Therapeutics Stock Surging On Monday? (Benzinga)
07:33AM	Monte Rosa joins with Novartis in molecular glue drug deal (BioPharma Dive)
07:00AM	Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders (GlobeNewswire)
Oct-23-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors (GlobeNewswire) -8.29%
Aug-28-24 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.50%
Aug-19-24 07:00AM	Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study (GlobeNewswire)

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

PresidentDr. Markus Warmuth M.D.

Ph.D.Mr. Philip Nickson J.D.

Ph.D.Mr. Filip Janku M.D.

Corporate Controller & Principal Accounting OfficerMr. Matthew Bowen

Chief Operating OfficerMs. Jennifer Champoux

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Warmuth Markus	President & CEO	Jul 16 '26	Sale	23.18	9,500	220,219	585,038	Jul 17 04:05 PM
Champoux Jennifer	Chief Operating Officer	Jul 15 '26	Option Exercise	3.98	4,351	17,317	66,722	Jul 16 04:10 PM
Champoux Jennifer	Chief Operating Officer	Jul 15 '26	Sale	23.38	4,351	101,730	62,371	Jul 16 04:10 PM
MARKUS WARMUTH	Officer	Jul 16 '26	Proposed Sale	23.18	9,500	220,219		Jul 16 04:05 PM
Champoux Jennifer	Officer	Jul 15 '26	Proposed Sale	23.38	4,351	101,730		Jul 15 04:12 PM
Townson Sharon	Chief Scientific Officer	Jul 06 '26	Option Exercise	6.14	6,000	36,840	73,845	Jul 07 04:41 PM
Townson Sharon	Chief Scientific Officer	Jul 06 '26	Sale	23.31	6,000	139,849	67,845	Jul 07 04:41 PM
Janku Filip	Chief Medical Officer	Jun 30 '26	Option Exercise	13.41	5,407	72,508	66,019	Jul 01 04:57 PM
Janku Filip	Chief Medical Officer	Jun 30 '26	Sale	24.50	5,407	132,472	60,612	Jul 01 04:57 PM
FILIP JANKU	Officer	Jun 30 '26	Proposed Sale	23.90	5,407	129,227		Jun 30 04:38 PM
Janku Filip	Chief Medical Officer	Jun 29 '26	Option Exercise	7.56	6,000	45,360	65,992	Jun 30 04:05 PM
Janku Filip	Chief Medical Officer	Jun 29 '26	Sale	22.95	6,000	137,700	59,992	Jun 30 04:05 PM
Manning Anthony M.	Director	Jun 29 '26	Option Exercise	4.16	10,000	41,600	10,000	Jun 30 04:05 PM
Manning Anthony M.	Director	Jun 29 '26	Sale	23.11	10,000	231,100	0	Jun 30 04:05 PM
FILIP JANKU	Officer	Jun 29 '26	Proposed Sale	22.29	6,000	133,740		Jun 29 04:45 PM
ANTHONY M MANNING	Director	Jun 29 '26	Proposed Sale	23.11	10,000	231,100		Jun 29 04:02 PM
Janku Filip	Chief Medical Officer	Jun 24 '26	Option Exercise	7.56	30,000	226,800	89,992	Jun 25 04:05 PM
Janku Filip	Chief Medical Officer	Jun 23 '26	Option Exercise	7.56	6,000	45,360	71,837	Jun 25 04:05 PM
Janku Filip	Chief Medical Officer	Jun 24 '26	Sale	21.42	30,000	642,681	59,992	Jun 25 04:05 PM
Janku Filip	Chief Medical Officer	Jun 23 '26	Sale	20.22	11,845	239,522	59,992	Jun 25 04:05 PM
Champoux Jennifer	Chief Operating Officer	Jun 23 '26	Option Exercise	3.98	2,175	8,656	64,546	Jun 25 04:05 PM
Champoux Jennifer	Chief Operating Officer	Jun 23 '26	Sale	20.00	2,175	43,500	62,371	Jun 25 04:05 PM
Townson Sharon	Chief Scientific Officer	Jun 23 '26	Option Exercise	6.14	3,000	18,420	70,845	Jun 25 04:05 PM
Townson Sharon	Chief Scientific Officer	Jun 23 '26	Sale	20.00	3,000	60,000	67,845	Jun 25 04:05 PM
FILIP JANKU	Officer	Jun 24 '26	Proposed Sale	20.71	30,000	621,300		Jun 24 04:34 PM
FILIP JANKU	Officer	Jun 23 '26	Proposed Sale	18.67	11,845	221,146		Jun 23 04:28 PM
Champoux Jennifer	Officer	Jun 23 '26	Proposed Sale	18.41	2,175	40,042		Jun 23 04:05 PM
EDMUND DUNN	Officer	Jun 23 '26	Proposed Sale	20.70	16,665	344,986		Jun 23 04:02 PM
Champoux Jennifer	Chief Operating Officer	Jun 17 '26	Option Exercise	3.98	2,176	8,660	64,547	Jun 18 04:05 PM
Champoux Jennifer	Chief Operating Officer	Jun 17 '26	Sale	19.00	2,176	41,344	62,371	Jun 18 04:05 PM
Townson Sharon	Chief Scientific Officer	Jun 17 '26	Option Exercise	6.14	3,000	18,420	70,845	Jun 18 04:05 PM
Townson Sharon	Chief Scientific Officer	Jun 17 '26	Sale	19.00	3,000	57,000	67,845	Jun 18 04:05 PM
Champoux Jennifer	Officer	Jun 17 '26	Proposed Sale	17.93	2,176	39,005		Jun 17 04:02 PM
Warmuth Markus	President & CEO	Jun 01 '26	Sale	19.44	5,466	106,253	594,538	Jun 02 04:05 PM
Warmuth Markus	Officer	Jun 01 '26	Proposed Sale	19.44	5,466	106,253		Jun 01 04:29 PM
Townson Sharon	Chief Scientific Officer	May 29 '26	Option Exercise	6.14	6,000	36,840	73,845	Jun 01 04:05 PM
Townson Sharon	Chief Scientific Officer	May 29 '26	Sale	19.87	6,000	119,220	67,845	Jun 01 04:05 PM
SHARON TOWNSON	Officer	May 29 '26	Proposed Sale	19.39	24,000	465,360		May 29 04:22 PM
Champoux Jennifer	Chief Operating Officer	May 27 '26	Option Exercise	3.98	2,175	8,656	64,546	May 28 07:10 PM
Champoux Jennifer	Chief Operating Officer	May 27 '26	Sale	20.00	2,175	43,500	62,371	May 28 07:10 PM
Champoux Jennifer	Officer	May 27 '26	Proposed Sale	19.33	2,175	42,043		May 27 04:01 PM
Champoux Jennifer	Chief Operating Officer	May 22 '26	Option Exercise	3.98	2,176	8,660	64,547	May 26 04:05 PM
Champoux Jennifer	Chief Operating Officer	May 22 '26	Sale	19.00	2,176	41,344	62,371	May 26 04:05 PM
Manning Anthony M.	Director	May 21 '26	Option Exercise	4.16	10,000	41,600	10,000	May 22 04:05 PM
Manning Anthony M.	Director	May 21 '26	Sale	18.01	10,000	180,100	0	May 22 04:05 PM
Champoux Jennifer	Officer	May 22 '26	Proposed Sale	18.72	2,176	40,735		May 22 03:59 PM
ANTHONY M MANNING	Director	May 21 '26	Proposed Sale	18.01	10,000	180,100		May 21 04:02 PM
Warmuth Markus	President & CEO	May 01 '26	Sale	18.92	5,467	103,447	600,004	May 05 04:05 PM
Warmuth Markus	Officer	May 01 '26	Proposed Sale	18.92	5,467	103,447		May 01 04:53 PM
EDMUND DUNN	Officer	Apr 16 '26	Proposed Sale	18.50	18,683	345,636		Apr 16 04:06 PM
Warmuth Markus	President & CEO	Apr 14 '26	Sale	17.64	8,000	141,125	605,471	Apr 15 04:05 PM
MARKUS WARMUTH	Officer	Apr 14 '26	Proposed Sale	17.64	8,000	141,125		Apr 14 04:39 PM
EDMUND DUNN	Officer	Apr 13 '26	Proposed Sale	18.00	16,687	300,366		Apr 13 04:06 PM
Nickson Philip	Chief Business & Legal Officer	Apr 09 '26	Sale	17.69	5,845	103,413	55,000	Apr 10 04:07 PM
PHILIP NICKSON	Officer	Apr 09 '26	Proposed Sale	17.69	5,845	103,413		Apr 09 04:05 PM
EDMUND DUNN	Officer	Apr 08 '26	Proposed Sale	17.25	26,117	450,623		Apr 08 04:08 PM
Dunn Edmund	Principal Accounting Officer	Mar 04 '26	Sale	17.96	139	2,496	22,554	Mar 05 05:24 PM
Warmuth Markus	President & CEO	Mar 02 '26	Sale	17.92	5,466	97,974	613,471	Mar 04 04:50 PM
Dunn Edmund	Officer	Mar 04 '26	Proposed Sale	17.86	139	2,482		Mar 04 04:44 PM
Dunn Edmund	Principal Accounting Officer	Feb 27 '26	Option Exercise	13.41	25,164	337,449	47,857	Mar 02 05:02 PM
Dunn Edmund	Principal Accounting Officer	Mar 02 '26	Option Exercise	13.41	536	7,188	23,229	Mar 02 05:02 PM
Dunn Edmund	Principal Accounting Officer	Feb 27 '26	Sale	18.10	25,164	455,506	22,693	Mar 02 05:02 PM
Dunn Edmund	Principal Accounting Officer	Mar 02 '26	Sale	17.50	536	9,380	22,693	Mar 02 05:02 PM
Warmuth Markus	Officer	Mar 02 '26	Proposed Sale	17.92	5,466	97,974		Mar 02 04:25 PM
Edmund Dunn	Officer	Mar 02 '26	Proposed Sale	17.50	536	9,380		Mar 02 04:15 PM
Edmund Dunn	Officer	Feb 27 '26	Proposed Sale	18.10	25,164	455,506		Feb 27 04:17 PM
Janku Filip	Chief Medical Officer	Feb 23 '26	Sale	19.50	9,189	179,161	65,837	Feb 24 04:05 PM
FILIP JANKU	Officer	Feb 23 '26	Proposed Sale	19.50	9,189	179,161		Feb 23 05:42 PM
Warmuth Markus	President & CEO	Jan 07 '26	Sale	23.49	5,466	128,373	618,937	Jan 09 04:05 PM
Warmuth Markus	Officer	Jan 07 '26	Proposed Sale	23.49	5,466	128,372		Jan 07 04:58 PM
Nickson Philip	Chief Business & Legal Officer	Jan 05 '26	Sale	15.17	3,155	47,861	60,845	Jan 05 04:06 PM
Champoux Jennifer	Chief Operating Officer	Jan 05 '26	Sale	15.17	2,629	39,882	62,371	Jan 05 04:05 PM
Dunn Edmund	Principal Accounting Officer	Jan 05 '26	Sale	15.17	1,039	15,762	22,693	Jan 05 04:04 PM
Warmuth Markus	President & CEO	Jan 05 '26	Sale	15.17	10,135	153,748	624,403	Jan 05 04:04 PM
Janku Filip	Chief Medical Officer	Jan 05 '26	Sale	15.17	3,155	47,861	75,026	Jan 05 04:04 PM
Warmuth Markus	Officer	Jan 05 '26	Proposed Sale	15.17	10,135	153,759		Jan 05 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GLUE

Monte Rosa Therapeutics Inc

Upgrade your Finviz experience